The information on our blog is for educational purposes only and is not investment or tax advice. Investors are advised not to invest until the respective company has been analysed and not to follow unfounded rumours and tips. Please be aware of the risks and costs associated with trading on the financial markets, as this is one of the riskiest investments in any form.
You are asked to share your knowledge and evidence of systematic misconduct, potential fraud and unethical behaviour via the anonymous portal on the BSE and NSE websites.
Trading and investment advice from Angel Broke preferred partners with active accounts.
Brokers accept the margin of value of their customers as a deposit to the Deposit System (WEF). Pay at least 20% upfront for each transaction value traded in the cash market segment.
By using this website, you agree to the Terms of Use and Privacy Policy. There is no way to prevent you from receiving this page in the future with the Privacy Pass. Sensex, BSE Quotes, Nifty and NSE Quotes are real-time quotes and licensed by BSE & NSE.
The future price of the Biocon share depends not only on the future prospects of present and potential Biocon investors, but also on the ongoing dynamics of investors with different trading styles. The price target is for the short, medium and long term. A well-managed price analysis by Biocon Ltd looks at and measures market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial debt and other key indicators.
It is considered overbought if the RSI value is above 70, and oversold if it is below 30. A better P / E shows that buyers are willing to pay better value per share when we talk about the evolution of expectations. Biocons indicators reflecting short-term sentiment are summarized in the following table.
Biocon Ltd Sharekhan 46,575 52,000 46,775 4,157 BUY Broker Report ShareKhan We reserve a purchase recommendation for the shares of Biocon after revising the PT to Rs. Biocon Ltd Geojit BNP Paribas Target $38,115 43,000 38,115 36.3% 17.07% BUY Report "We expect a long-term sustained growth for Biocon due to a strong pipeline of start-ups and increased investment.